October is over and November is here, which means it's time to turn over your calendars and check out the latest edition of #TheAxon newsletter!
关于我们
Neurology Live is your trusted news source for breaking drug approvals, pipeline trials and emerging trends in neurology. The digital and print publication provides physicians and other healthcare professionals with up-to-date disease-specific news, clinical information and other resources that can help them provide better care to patients. At Neurology Live, you'll find in-depth conference coverage and information about upcoming meetings, content from our affiliated print journals, video interviews with leading physician experts and other multimedia resources. Get all the latest news on individual medical conditions in our condition centers: ? Dementia & Alzheimer Disease ? Epilepsy ? Headache & Migraine ? Movement Disorders ? Multiple Sclerosis ? Neuromuscular ? Sleep Medicine ? Stroke
- 网站
-
https://neurologylive.com/
NeurologyLive的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 201-500 人
- 总部
- Cranbury，New Jersey
- 类型
- 私人持股
- 领域
- Dementia、Alzheimer Disease、Epilepsy、Migraine、Headache、Movement Disorders、Parkinson Disease、Huntington Disease、Tardive Dyskinesia、Multiple Sclerosis、Sleep Medicine、Stroke和Neuromuscular
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury，08512
NeurologyLive员工
动态
-
Recent topline results from the phase 2 DIMENSION study of SAGE-718 showed that the treatment did not meet primary or secondary end points in patients with cognitive impairment associated with #Huntington disease. Sage Therapeutics https://lnkd.in/emKAne7S
Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results
neurologylive.com
-
Preliminary data from a single-arm, prospective, non-randomized phase 2 trial revealed that sumatriptan, a #migraine-specific medication, may alleviate the symptom burden for patients with post-traumatic #headache. University of Washington - School of Medicine https://lnkd.in/ex5WM8Bm
Sumatriptan Demonstrates Therapeutic Potential in Post-Traumatic Headache in Phase 2 Pilot Study
neurologylive.com
-
In a recent study, treatment with deferiprone, 15 mg/kg twice a day, worsened cognitive performance in patients with amyloid-confirmed #MCI and mild #AD, underscoring the critical role of iron in cognition in the disease and raises intriguing questions. JAMA Neurology https://lnkd.in/eMwzG-ED
Negative Effect of Deferiprone Points to Impact of Iron Lowering in Alzheimer Disease
neurologylive.com
-
New details have emerged regarding a multicenter, open-label, phase 2 study, dubbed KYSA-6 (NCT06193889) that will investigate the efficacy and safety of KYV-101 (Kyverna Therapeutics), an investigational fully human anti-CD19 CAR T-cell therapy, in patients with refractory generalized myasthenia gravis. Our coverage: https://lnkd.in/ejw9vn69
Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented
neurologylive.com
-
In a phase 3 study, treatment with triheptanoin did not have a significant impact vs placebo in the frequency of disabling movement disorders among patients with glucose transporter type 1 deficiency syndrome. #AANEM2024 https://lnkd.in/ebFF8iFT
Triheptanoin Shows No Significant Effect on Movement Disorder Events in Glut1 Deficiency Syndrome
neurologylive.com
-
At #MDSCongress 2024, investigators outlined a phase 2a trial evaluating lamotrigine, an FDA-approved antiseizure drug, for dementia with Lewy bodies. The study, which will enroll 60 patients aged 60 years and older from a hospital in Seoul, Korea, is estimated to be completed in early 2025. Read more: https://lnkd.in/g_jM9YAC
Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies
neurologylive.com
-
A newly presented analysis of the phase 3 ADAPT-SC study (NCT04818671) revealed that treatment with subcutaneous efgartigimod PH20 (Vyvgart Hytrulo; argenx) was safe and efficacious in patients with seronegative generalized myasthenia gravis. https://lnkd.in/eHWH_C9v
Subcutaneous Efgartigimod Demonstrates Efficacy, Safety in Seronegative Myasthenia Gravis
neurologylive.com
-
A recently presented post-hoc analysis of the long-term, RAISE-XT study at #AANEM 2024 highlighted the high compliance rates of zilucoplan, a recently approved complement C5 inhibitor for generalized #MyastheniaGravis. UCB American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) https://lnkd.in/evpqz35d
Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis
neurologylive.com
-
Lara Jehi, MD, MHCDS, of Cleveland Clinic, discussed the scalability of scalp #EEG as a diagnostic tool, highlighting its accessibility in low-resource settings compared with resource-intensive techniques like intracranial EEG or functional #MRI. #EpilepsySurgery https://lnkd.in/eKEhe-Hx
Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS
neurologylive.com